# US 2006/0052387 A1 · Organic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0052387 A1
- Document ID: US20060052387A1
- Status: Published application
- Kind: A1
- Application number: 10/519,654
- Filed: 2003-06-26
- Published: 2006-03-09
- Earliest claimed: 2002-06-26
- Inventors: Clay Marsh
- Web page: https://patentgrep.com/patent/US20060052387A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2ylamino)phenyl]benzamide of the formula (I): or a pharmaceutically acceptable salt thereof for the treatment of inflammation.

## Claims

### Claim 1

A method for reducing inflammation in a subject, the method comprising administering an anti-inflammatory effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of Compound I
or a pharmaceutically acceptable salt thereof to the subject in need of such treatment.

### Claim 2 (depends on 1)

The method of claim 1 wherein the pharmaceutically acceptable salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula I is an acid addition salt.

### Claim 3 (depends on 1)

The method of claim 1 wherein the pharmaceutically acceptable salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula I is a monomethanesulfonate salt.

### Claim 4 (depends on 1)

The method of claim 1 wherein the inflammation involves monocytes.

### Claim 5 (depends on 4)

The method of claim 4 wherein the inflammation involves macrophage colony stimulating factor (M-CSF)-stimulated monocytes.

### Claim 6 (depends on 4)

The method of claim 4 wherein the inflammation is involved in conditions selected from the group consisting of autoimmune diseases, arthritis, and lung injuries.

### Claim 7 (depends on 1)

The method of claim 1 wherein the inflammation is chronic.

### Claim 8 (depends on 1)

The method of claim 1 wherein the inflammation is acute.

### Claim 9 (depends on 1)

The method of claim 1 wherein the subject is a mammal.

### Claim 10 (depends on 9)

The method of claim 9 wherein the subject is a human subject.

### Claim 11 (depends on 1)

The method of claim 1 wherein the anti-inflammatory effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or pharmaceutically acceptable salt thereof is in the range from 10 mg to 1000 mg.

### Claim 12 (depends on 11)

The method of claim 11 wherein the anti-imflammatory effective amount is in the range from 50 mg to 600 mg.

### Claim at position 13

13-27. (canceled)

### Claim 28 (depends on 2)

The method of claim 2 wherein the inflammation involves monocytes.

### Claim 29 (depends on 28)

The method of claim 28 wherein the inflammation involves macrophage colony stimulating factor (M-CSF)-stimulated monocytes.

### Claim 30 (depends on 28)

The method of claim 28 wherein the inflammation is involved in conditions selected from the group consisting of autoimmune diseases, arthritis, and lung injuries.

### Claim 31 (depends on 3)

The method of claim 3, wherein the inflammation involves monocytes.

### Claim 32 (depends on 31)

The method of claim 31 wherein the inflammation involves macrophage colony stimulating factor (M-CSF)-stimulated monocytes.

### Claim 33 (depends on 31)

The method of claim 31 wherein the inflammation is involved in conditions selected from the group consisting of autoimmune diseases, arthritis, and lung injuries.

### Claim 34 (depends on 2)

The method of claim 2 wherein the anti-inflammatory effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or pharmaceutically acceptable salt thereof is in the range from 10 mg to 1000 mg.

### Claim 35 (depends on 3)

The method of claim 3 wherein the anti-inflammatory effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or pharmaceutically acceptable salt thereof is in the range from 10 mg to 1000 mg.
